Sipuleucel-T, an autologous active cellular immunotherapy, has shown evidence of efficacy in reducing the risk of death among men with metastatic castration-resistant prostate cancer. In this ...

The therapy is called autologous transplant ... The other form of blood stem cell transplantation — called “allogeneic,” meaning that the cells come from another person — has long been recognized as a ...

CAR-Ts are revolutionising the treatment of blood cancers such as B-cell acute lymphocytic leukaemia. However, their success ...

Now a new approach using donor cells brings the hope of giving off-the-shelf CAR T cell immunotherapy to patients in as little as five days. Conventional autologous CAR T therapy requires cells to be ...

The majority of autologous CAR-T cell therapies involve ... Fate Therapeutics is at the forefront of programmed cellular immunotherapy developments designed to treat cancer and immune disorders.

CERo Therapeutics Holdings, Inc. (Nasdaq: CERO) (“CERo”), an innovative immunotherapy company seeking to advance the next ...

The funding includes contributions from new investors such as Baylor College of Medicine and the Brain Tumor Investment Fund.

Late-breaking research reveals there is no benefit from high-dose chemotherapy followed by autologous stem cell transplant ... such as intensive chemotherapy, immunotherapy, targeted drugs ...

The Philadelphia-based company’s presentations will focus on IGV-001, a novel autologous cell immunotherapy designed for ...

“This second FDA Fast Track designation of our autologous dendritic cell vaccines for pancreatic cancer is another acknowledgement of the incredible potential of this innovative immunotherapy ...